Supplement Claims For Drug/Therapy Augmentation Clarified By FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA is pulling back slightly from its proposed stance restricting dietary supplement claims for augmentation of drugs or therapies in the structure/function claims final rule published Jan. 6. However, the agency continues to believe such claims should not refer specifically to a disease.
You may also be interested in...
CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.
CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.
CRN Says GSK Swings Wide Against Alli Competition With Weight-Loss Petition
The Council for Responsible Nutrition says GlaxoSmithKline's request that FDA reclassify weight-loss claims as disease claims would essentially eliminate nonprescription competition for GSK's OTC drug alli and "cripple the dietary supplement category.